Data rooms for pharma startups.
Pharma startups, including reformulation and specialty drug companies, are judged on the regulatory route to approval, manufacturing readiness, exclusivity and patent life, and commercial potential. The room should hold the development plan, FDA correspondence, CMC and supplier files, clinical data, the patent and exclusivity analysis and market research.
Pharma room
- 01 Corporate
- 02 Development plan
- 03 FDA correspondence
- 04 Nonclinical
- 05 Clinical
- 06 CMC
- 07 Supply
How it works for a startup.
Not every drug startup develops a new molecule. Many pursue the 505(b)(2) pathway, building on existing safety data for a new formulation, route or indication. Diligence then focuses on what data the company can rely on, the bridging studies needed and the exclusivity the product can earn.
Manufacturing is a common weak point. Reviewers ask for the chemistry, manufacturing and controls package, active ingredient supply, references to drug master files held by suppliers, CDMO agreements and stability data. A single-source supplier without a backup is a frequent finding.
Pharma licensing and partnering processes involve business development teams at larger companies who review many rooms at once. Clear summaries per topic and a fast Q&A help a small company stand out, while view-only access protects data that has not been published.
Top 10 data rooms for this job.
Our five measures, re-weighted for pharma. Places 11 to 17 are listed below the cards.
- Setup speed 16%
- Investor experience 16%
- Access control 28%
- Diligence tools 23%
- Startup pricing 18%
- 1 9.1/10First-rate
- $149 monthly
- 14-day free trial
- 8/12 feature checks
- Investor Q&A
- NDA e-signing
- Dynamic watermarks
- View-only and download control
- SOC 2 (hosting)
- 2 8.2/10Strong pick
- Quote only
- Free trial offered
- 9/12 feature checks
- Investor Q&A
- Dynamic watermarks
- View-only and download control
- Viewer activity log
- SOC 2
- ISO 27001
- GDPR
- 3 8.1/10Strong pick
- Quote only
- Demo, no trial
- 10/12 feature checks
- Investor Q&A
- Dynamic watermarks
- View-only and download control
- Viewer activity log
- SOC 2
- ISO 27001
- GDPR
- 4 8.1/10Strong pick
- Quote only
- Free trial offered
- 8/12 feature checks
- Investor Q&A
- Dynamic watermarks
- View-only and download control
- Viewer activity log
- SOC 2
- ISO 27001
- 5 8.0/10Strong pick
- Quote only
- Free trial offered
- 7/12 feature checks
- Investor Q&A
- Dynamic watermarks
- View-only and download control
- Viewer activity log
- SOC 2
- ISO 27001
- 6 7.9/10Strong pick
- $250 monthly
- Free trial offered
- 8/12 feature checks
- Investor Q&A
- NDA e-signing
- Dynamic watermarks
- View-only and download control
- SOC 2
- 7 7.7/10Good option
- Quote only
- Demo, no trial
- 8/12 feature checks
- Investor Q&A
- Dynamic watermarks
- View-only and download control
- Viewer activity log
- SOC 2
- ISO 27001
- GDPR
- 8 7.7/10Good option
- $299 monthly
- Free trial offered
- 7/12 feature checks
- Investor Q&A
- Dynamic watermarks
- View-only and download control
- Viewer activity log
- SOC 2
- 9 7.7/10Good option
- Quote only
- Demo, no trial
- 8/12 feature checks
- Investor Q&A
- Dynamic watermarks
- View-only and download control
- Viewer activity log
- SOC 2
- ISO 27001
- 10 7.6/10Good option
- $55 monthly
- Free trial offered
- 9/12 feature checks
- NDA e-signing
- Dynamic watermarks
- View-only and download control
- Viewer activity log
- SOC 2
- ISO 27001
- HIPAA
Show places 11 to 17
- DealRoom 7.5
- SmartRoom 7.5
- ShareVault 7.3
- Onehub 7.0
- Digify 6.7
- Venue by DFIN 6.6
- DocSend 6.2
Folder index.
A starting structure for this room. Rename folders to fit your company and keep the numbers.
Charter, cap table, financing documents, board consents.
Target product profile, pathway rationale, timeline to approval.
Meeting packages and minutes, IND, special designations.
Pharmacology and toxicology reports, literature relied on.
Protocols, study reports, bioequivalence or bridging studies.
Process description, specifications, stability, DMF letters of authorization.
API and CDMO agreements, supplier audits, second source plans.
Patent families, expected Orange Book listings, regulatory exclusivity analysis.
Market research, pricing and payer analysis, forecast.
In-licence agreements, term sheets, option agreements.
Need every file by stage? Use the startup data room checklist.
Must-have features.
| Provider | View-only and download control | Dynamic watermarks | Investor Q&A | Viewer activity log |
|---|---|---|---|---|
| Ellty | ||||
| iDeals | ||||
| Datasite | ||||
| Ansarada | ||||
| Firmex | ||||
| SecureDocs | ||||
| Drooms | ||||
| CapLinked | ||||
| Intralinks | ||||
| Citrix ShareFile |
- View-only and download control
- Set each file to view only, print or download, and change it later without resending anything.
- Dynamic watermarks
- Stamps the viewer email and the time across every page, so a forwarded screenshot points back to its source.
- Investor Q&A
- Funds and buyers ask questions against a file; you assign, answer and publish replies, and the thread stays on record.
- Viewer activity log
- Shows which investor opened which file, for how long and when, and exports the record.
Set up the room in 6 steps.
- 1
Lead with the target product profile
Put the TPP and pathway rationale at the top so reviewers understand the plan before the data.
- 2
Summarise exclusivity
List expected patent protection and regulatory exclusivities with dates, reviewed by counsel.
- 3
Complete the CMC folder
Collect specifications, stability data, supplier agreements and DMF authorization letters.
- 4
Flag supply risk
Note single-source suppliers and the plan for a second source.
- 5
Open by partner
Give each partner its own access group, view-only, and track activity to judge interest.
- 6
Answer through Q&A
Collect partner questions in one place and answer with links to data.
Common mistakes.
- No clear view of which earlier data the 505(b)(2) application will rely on.
- Single-source active ingredient supply with no backup.
- Exclusivity estimates without counsel review.
- Forecasts that ignore payer pricing pressure.